Seydel, Gonul SeydaAyan, DurmusBalci, TevfikBayraktar, MuhammetGunturk, Inayet2024-11-072024-11-0720230363-02691532-432Xhttps://doi.org/10.1080/03630269.2023.2206971https://hdl.handle.net/11480/14587Hemoglobinopathies are one of the most widespread hereditary disorders in Turkey. The present study aimed to determine the prevalence of hemoglobinopathies in the Nigde province of Turkey. This study was conducted with 2013 individuals who applied for the premarital screening, between January 2019 and December 2021. The complete blood count was measured by an automated hematology analyzer. The types of hemoglobin were determined by high-performance liquid chromatography. A total of 2013 individuals including 951 (47.2%) females and 1062 (52.8%) males, were screened within the premarital screening program, and 67 (3.3%) of them were migrants. 53 out of 2013 (2.63%) individuals were identified as beta thalassemia carriers, and five of them were migrants including two from Afghanistan, two from Iran, and one from Georgia. HbC was observed in two cases, a couple from Syria (0.1%), HbD in two cases (0.1%), HbE in one case from Thailand (0.05%), HbS-beta-thalassemia in one case (0.05%), delta-beta thalassemia in one case (0.05%), and unidentified structural variant in one case (0.05%). Moreover, 183 individuals (9.1%) were considered to have iron deficiency, alpha-thalassemia, or silent beta-thalassemia carrier. These results indicate that the province of Nigde is a relatively risky region regarding hemoglobinopathies. Geographic location and immigrant population may have slightly affected the local prevalence of hemoglobinopathies and could be taken into consideration to ensure the effective implementation of the hemoglobinopathy prevention program.eninfo:eu-repo/semantics/closedAccessHemoglobinopathiesthalassemiapremarital screeningTurkeymigrantsPrevalence of Hemoglobinopathies in Premarital Screening in the Province of Nigde, TurkeyArticle472364110.1080/03630269.2023.2206971371841182-s2.0-85159305495Q3WOS:000988935100001Q4